# Patient Preference Study: Standard of Care Versus Once-daily Trientine Tetrahydrochloride

> **NCT07010575** · PHASE2 · COMPLETED · sponsor: **Orphalan** · enrollment: 10 (actual)

## Conditions studied

- Wilson's Disease

## Interventions

- **DRUG:** New TETA 4HCl Formulation
- **DRUG:** Standard of Care

## Key facts

- **NCT ID:** NCT07010575
- **Lead sponsor:** Orphalan
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2025-07-15
- **Primary completion:** 2025-12-18
- **Final completion:** 2025-12-18
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2026-04-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07010575

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07010575, "Patient Preference Study: Standard of Care Versus Once-daily Trientine Tetrahydrochloride". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07010575. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*